Board

Board members

Annette Clancy, Chairman of the Board and Independent Director

Annette Clancy

Annette Clancy has more than 30 years of experience in the pharmaceuticals industry, mainly at GlaxoSmithKline (GSK). She held several posts at GSK in the USA and the UK notably in R&D, global marketing and licensing strategy, and commercial development. Until 2008 she was Head of International Transactions and Alliance Management, responsible for delivering innovative partnerships on early-stage drugs, international commercial alliances and mergers and acquisitions. Since then, Annette has concentrated on working with healthcare biotech companies. She is currently the Non-Executive Chairman of three private European companies: ObsEva, Lysogene and ENYO Pharma. Annette is also a Non-Executive Director at SOBI and a Senior Advisor to Frazier Healthcare, a US venture capital group specialising in the healthcare sector.

Jason Dinges, PhD, JD

Jason Dinges

Jason Dinges has been a member of the investment team at Morningside since 2011, and has extensive experience providing operational and management oversight to early-stage biotechnology companies. He serves on the boards of Morningside’s portfolio companies Matatu, Inc., Cancer Targeting Systems, Inc., 2020, Inc., and Vigeo, Inc. Jason received his B.S. from Illinois Wesleyan University, a Ph.D. in genetics from Iowa State University, and his J.D. from the University of Iowa College of Law, with highest distinction. He spent 5 years as an intellectual property attorney with Foley & Lardner LLP, before joining Morningside Technology Advisory LLC.

Dr Jean-Jacques Garaud, MD

Jean-Jacques Garaud

  • Founder/CEO of ADV Life Science SA
  • CEO of Inotrem SA
  • A senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012)
  • Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
  • Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
  • Previously held other senior positions with Shering-Plough in the USA (1991 to 2001) and with Novartis in the USA and Switzerland (2001 to 2007)
  • Known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C virus in the 90s
  • Board member of Circassia, Polyphor, MedDay and Inatherys

Chahra Louafi

Chahra Louafi

Chahra Louafi is Senior Investment Director and Head of the Biotherapies and Rare Diseases Fund of Bpifrance (formerly CDC Entreprises). Before joining CDC Entreprises in 2001, Chahra Louafi was in charge of project development and company creation for a private incubator that specialised in biotechnologies. Chahra Louafi is Vice-Chairman of the Supervisory Board of Inserm Transfert Initiative and a member of the Supervisory Board of Cap Decisif Management. Chahra Louafi also sits on the Boards of Directors of DBV Technologies, Eyevensys, Sensorion, MedDay, Pixium Vision, Lysogene, Annapurna Therapeutics and BrainEver.

Rafaèle Tordjman, MD, PhD

Rafaèle Tordjman

Rafaèle Tordjman, MD, PhD, is a Managing Partner. She joined Sofinnova Partners in 2001. Prior to this, she worked as a research scientist at the Institut National de la Recherche Médicale (INSERM) in Cochin Hospital, Paris. Before joining INSERM, she was a medical doctor specializing in clinical haematology and internal medicine. She obtained her PhD, with high honours, in haematopoiesis and angiogenesis from the University Paris VII followed by a post doctoral fellowship in immunology. Rafaèle obtained her medical degree and her specialisation in Haematology and Internal Medicine as a five-year fellow in Paris University Hospitals. She also participated in the “Young Manager Program” at INSEAD (France, in 2002). She has invested in and is on the board of Ascendis, DBV technologies – which went public on Euronext Paris and on Nasdaq, Nucana Biomed, MedDay, ObsEva and Lysogene. She was also on the board of Corevalve, Endoart before it was successfully sold to Allergan Inc, of Preglem before the latter was successfully sold to Gedeon Richter, HBI Ltd before being acquired by Meda and off Flexion Therapeutics – which went public on Nasdaq.

Dr Jacky Vonderscher, PhD, Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys and ObsEva and SAB member of Inotrem

Dr. Timothy M. Wright, PhD, Independent Administrator

Timothy Wright

Timothy M. Wright is the Executive Vice-President for Research and Development at Regulus, a Californian Biotech company and until recently, was the Executive Vice President of Translational Sciences at the California Institute for Biomedical Research (Calibr). With degrees in Biology from the University of Delaware and Medicine from John Hopkins University (Rheumatology, Immunology and Molecular Biology), Timothy entered the pharmaceutical industry after a brilliant academic career at John Hopkins and the University of Pittsburgh. Over more than 14 years, initially with Pfizer and then Novartis, Timothy directed early-stage and clinical research programmes. He was Global Head of Development at Novartis in Basel, Switzerland. Timothy has been the Scientific Adviser to several organisations, including the Bill and Melinda Gates Foundation.

Board observers

Pr Patrice André, MD, PhD, Medical Advisor

Patrice André

  • Professor of Virology, Charles Mérieux Lyon Sud Medical School, Lyon 1 University
  • Head of clinical virology department at the Hospices Civils de Lyon
  • Team leader at the International Center for Infectiology Research
  • Post-doctoral fellow at New Mexico University
  • > 200 publications in international peer review and high-impact journals, inventor on 7 patents
  • Former member at several scientific committees (Hospices Civils de Lyon, Inserm)
  • Former expert at AFSSAPS
  • Member of several ANRS commissions

Dr Vincent Lotteau, PhD, Scientific Advisor

Vincent Lotteau

  • Inserm Research Director, Immunologist
  • Team leader at the International Center for Infectiology Research
  • Member of the Laboratory of Excellence “Ecofect”
  • Founder of the technology transfer team
  • Former director of Inserm Unit « Fundamental and clinical immunology »
  • Former member of Inserm-Transfert steering committee
  • Participated to several governmental missions
  • Post-doctoral fellow at Harvard University and Scripps Clinic Research Foundation
  • Inventor on 9 patents
  • European expert for systems biology

Sara Núñez-Garcia, PhD, MBA

Sara Nunez-Garcia

Sara Núñez-Garcia joined the Life Sciences team as an Associate in 2013; Sara focuses on investments in the biopharmaceutical sector. Prior to Sofinnova Partners, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space. Previously, Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam. Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets. She has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors. Sara has published eighteen peer-reviewed articles and patents. Sara also holds an MBA from INSEAD.

François Thomas, PhD, MBA

François Thomas

François Thomas has more than 25 years of experience in the life sciences sector.Before becoming Manager Partner of Inserm Transfert Initiative in 2014, he held management positions at Ipsen (VP Clinical Development and CMO) and Genset (VP Licensing and Pharmacogenomics). In 2002, François became Partner at Atlas Venture and in 2006 he was responsible for healthcare corporate finance at the bank Bryan Garnier. Most recently, he was CEO of Cytheris, a private biotech company. François has been a board member of several biotech companies such as Eurogentec YMB and Gamamabs, as well as representative of Atlas and ITI in over 20 boards. In addition, in 1995 François founded a consultancy company called Bioserve Ltd. François is medical oncologist, a former assistant professor at the Gustave Roussy Institute, and holds a Ph. D in molecular oncology and an MBA from MIT (Boston).